• Search

Search in Site

Industry news and analysis across pharma and medical devices PharmaDeviceNews.com

  • Home
  • Pharma & Biotech
  • Medical Devices & Diagnostics
  • Features & Analysis
  • Privacy Policy
  • About PharmaDeviceNews
  • Editorial Policy
  • Disclaimer
  • Contact Us
Home»Posts tagged with»opioid reduction

Why Pacira BioSciences, Inc. is positioning EXPAREL as a cost-saving tool in Medicare surgery

By Soujanya Ravi on April 27, 2026   Pharma & Biotech  

Why Pacira BioSciences, Inc. is positioning EXPAREL as a cost-saving tool in Medicare surgery

Find out how Pacira BioSciences, Inc.’s EXPAREL data could reduce opioid use and surgical costs in Medicare patients.

Can UT Health San Antonio’s GRK2 inhibitor reduce opioid use in burn trauma care?

By Pallavi Madhiraju on January 15, 2026   Pharma & Biotech  

Can UT Health San Antonio’s GRK2 inhibitor reduce opioid use in burn trauma care?

Can UT Health San Antonio’s GRK2-targeted therapy reduce opioid use and scarring in burn trauma? Find out what’s next for this emerging dual-action approach.

Recent Posts

  • Nuvalent’s ALK inhibitor gets Priority Review as lung cancer treatment sequencing evolves
  • Can Eli Lilly’s $3bn Haisco deal deepen big pharma’s China drug discovery pipeline?
  • Cirius Therapeutics puts CIR-0602K in the spotlight as ADA 2026 turns to metabolic complexity
  • AstraZeneca’s Imfinzi gains a first-mover edge in high-risk non-muscle-invasive bladder cancer
  • Can Ono and Deciphera turn ONO-4578 into a global Phase 3 oncology contender?
  • Ranok Therapeutics pushes RNK08954 forward as KRAS G12D drug development heats up
  • Can Servier’s $2.65bn Edgewise deal reshape the muscular dystrophy drug race?
  • Can Convergent Therapeutics define the next prostate cancer standard after Lu-PSMA therapy?
  • Why T-CURX’s Pantherna acquisition could matter for the future of cell therapy manufacturing
  • Is Amgen’s bispecific lung cancer drug becoming a global standard after chemotherapy failure?
  • Fulgent Genetics’ oncology pivot gets sharper as FID-007 shows Phase 2 activity at ASCO 2026
  • Minghui and Qilu push MHB088C forward as prostate cancer ADC race tightens
    • About PharmaDeviceNews
    • Contact Us
    • Disclaimer
    • Editorial Policy
    • Privacy Policy
© 2026, ↑ PharmaDeviceNews
Log in - Powered by WordPress - Gabfire Themes